Aluda Pharmaceuticals Announces Peer-Reviewed Publication on ALD-R491, an Exosome Release Inhibitor That Reduces Cancer Cell Mobility

Aluda Pharmaceuticals, a private company, announced the publication of an article in a peer-reviewed journal describing a novel mechanism of exosome release inhibition (ExoRI) for the treatment of a broad range of cancers.  Over the past decade, tumor exosomes have been studied extensively in academia for their roles carrying signals that make tumors invasive, creating a tumor microenvironment (TME) that enables evasion from immune detection, and promoting metastases.  Tumor cells upregulate their release of exosomes to promote these roles throughout all stages of cancer, across many types of cancers, transporting multiple pro-cancer signals, many of which are existing drug targets. Inhibition represents a way to block many signals at once, even as they change over time. Research has shown that PD-L/PD-L1, the important immune checkpoint targets, avoid detection by their transport in exosomes, so exosome inhibitors may also address the large rate of non-response for that class of agents.

Login Or Register To Read Full Story